Summary of COVID-19 apremilast studies
1. Amgen et al., Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
515 patient apremilast late treatment RCT: 1% higher mortality (p=1), 8% worse improvement (p=0.73), 11% lower hospital discharge (p=0.56), and 11% worse recovery (p=0.58).RCT 384 hospitalized patients showing no significant difference with apremilast treatment.
Apr 2022, Amgen, NCT04590586, https://s3.amazonaws.com/trs-cor-9011/5014875/a260bd53-20a7-42af-8426-45d8d9087cf8/8b07f953-29ef-4571-855b-2a7918c21449/Public_Registration_(Study_Level)_-_Plain_Language_Summary_of_Results_V01_Global.en_-_07-Apr-2022_English-v1.pdf, https://c19p.org/amgen
2. Files et al., Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial
210 patient apremilast late treatment RCT: 5% higher mortality (p=0.85) and 28% worse recovery (p=0.22).RCT severe COVID-19 patients showing no significant difference in outcomes with apremilast.
Mar 2023, eClinicalMedicine, https://www.sciencedirect.com/science/article/pii/S2589537023000664, https://c19p.org/filesapr